1) The study of effect of N-acetyl Cysteine(NAC) & Metformin co-treatment on Biochemical factors of follicular fluid, Oocytes and Embryos quality in patients with PCOs and undergoing ICSI treatment.
2)Through a prospective experimental study designed as a clinical trial, 60 infertile patients diagnosed with PCOS who were referred to IVF Unit of the Reproductive Health Research Center of Gom were enrolled. Overall, considering a 95% confidence interval and 80% power, 60 patients were required as the sample population.
3) Inclusion criteria dictated that the patients needed to fulfill PCOS diagnostic criteria based on the Rotterdam consensus workshop in 2003 . That is, in order to be enrolled, each patient needed to
have two out of three chronic oligo or anovulation criteria, clinical or biochemical hyperandrogenism
or polycystic ovaries at sonography examination.
Presence of infertility factors other than anovulation, pelvic organic pathologies, congenital
adrenal hyperplasia, thyroid dysfunction, Cushing’s syndrome, hyperprolactinemia, androgen secreting neoplasia, diabetes mellitus , severe hepatic or kidney diseases, and active peptic ulcer
were considered as exclusion criteria.
4) All patients were advised to avoid any change in their physical activity and nutrition and not to undergo any new pharmacotherapy during the study. Patients were asked to report any possible adverse effects.
Patients were divided into four groups considering the similarity of compound confounding variables and randomized in order to minimize the effects of confounding factors through a randomized method.
1)Group-M, cases received treatment with Metformin (started with 500 mg three times daily).
2)Group-N, cases received N-acetyl cysteine, 1.8 gm/day (600 mg three times daily).
3)Group-MN, cases received N-acetyl cysteine, 1.8 gm/day (600 mg three times daily)+ Metformin (started with, 500 mg three times daily).
4) 2)Group-P, the control group took placebo (ORS, Poursina, Tehran, Iran, batch no.30).